Athenex, Inc.
Athenex, Inc. (ATNX): 4 pipeline candidates · ~15 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
15.1 months
D/E -35.08 · 0% dilution
Lead: Phase 1
4 candidates
N/A
N/A
A transparent, data-derived signal for Athenex, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$30.4M
Quarterly Burn
$11.8M
Runway
15.1 mo
Revenue
$8.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| kur-501 | Phase 1 |
| kur-502 | Phase 1 |
| kur-503 | Preclinical |
| tcrt-eso-a2 | Phase 1 |
Frequently asked questions
How many drug candidates are in Athenex, Inc.'s pipeline?
Athenex, Inc. (ATNX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Athenex, Inc.'s lead drug candidate?
Athenex, Inc.'s most advanced tracked candidate is kur-501 (Phase 1) for relapsed-refractory high risk neuroblastoma.
What is Athenex, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Athenex, Inc. has approximately 15.1 months of cash runway.
Who is the CEO of Athenex, Inc.?
Special Meeting is the chief executive officer of Athenex, Inc. (ATNX).
Get the full picture on Athenex, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.